What is the translation of " EVALUABLE " in Chinese?

• 名可评估
• 例可评估
• 可评估
• 例
• 可评价

Examples of using Evaluable in English and their translations into Chinese

Must have evaluable disease.
则必须有可测量的疾病。

A total of 19 patients were enrolled and 14 were evaluable.
总共纳入了19名患者，其中可评估14人。

Of the evaluable cycles, 3.9% have a severe diarrhoea.
在可评估的周期内，3.9%出现严重腹泻。

Of the 114 countries approached, 95 had evaluable information.
在涉及的114个国家中，95个有可评价的资料。

Measurable or evaluable disease as defined by RECIST v1.1.
必须有根据RECISTv1.1确定的可测量的疾病。

Complete remissions(CR) were observed in 5 of the 7 evaluable patients.
例可评估患者中有5例观察到完全缓解（CR）。

Among 46 patients evaluable at 6 months, CR was 30% and partial response(PR) rate was 7%.
在6个月（n=46）可评价的患者中，CR率为30％，PR率为7％。

Based on independent radiological review, responses were observed in 14 of the 27 evaluable patients.
根据独立的放射学审查，在27例可评估患者中有14例观察到反应。

Among the 46 patients evaluable at 6 months, the CR rate was 30 percent and PR rate was 7 percent.
在6个月（n=46）可评价的患者中，CR率为30％，PR率为7％。

Of the 37 subjects, the post-transplant virologic response(pTVR) rate is 64%(23/36) in the 36 evaluable subjects who have reached the 12 week post-transplant time point.
对37例，移植后的病毒学应答（PTCR）率为64%（23/36）在36例受试者均达到移植后12周时间点。

In 26 evaluable AML patients, there were 4 complete remissions(CR/CRi) and one partial remission(PR).
在26例可评估的AML患者中，有4例完全缓解（CR/CRi）和1例部分缓解（PR）。

At a median follow-up of 56.8 months, 60%(n= 159) of 267 evaluable patients achieved major cytogenic response(MCyR).
在8个月的随访期间，267名患者中60％（n=159）达到显着的细胞遗传学缓解（MCyR）。

The study included 28 evaluable patients, more than two thirds of whom were considered to be of average risk for colorectal cancer.
该研究包括28名评估患者，其中三分之二以上被认为具有结直肠癌的平均风险。

The case studies were selected in order to capture a comprehensive and evaluable picture of UNDP activities across the diversity of conflict-affected circumstances in which it works.
选择这些案例研究的目的在于全面了解和评价开发署在各种受冲突影响局势中开展活动的情况。

For 124 evaluable patients for concordance analysis, researchers compared genetic changes in the tumors to those in circulating tumor DNA from the blood samples.
对于124例可评估患者的一致性分析，研究人员将肿瘤的遗传变化与血液样本循环肿瘤DNA的变化进行比较。

Among 83 patients with samples evaluable for PD-L1 expression, 37(45%) had PD-L1- positive tumors;
在83名可评估PD-L1表达的样品中，37名(45%)具有PD-L1阳性肿瘤;

There were 46 evaluable patients in total, and 43 of them(94%) achieved a complete cytogenetic response(CCyR) at 6 months.
共有46名可评估的患者，并且第6个月时其中43名（94%）达到完全细胞遗传学缓解（CCyR）。

The objective response rate(ORR) for all evaluable patients was 14% and the ORR rate for patients with PD-L1+ expression was 23%.
对于所有可评价的患者，客观缓解率（ORR）为14%，但PD-L1阳性表达患者升高至23%。

Across all 22 evaluable patients, the data showed an objective response rate(ORR) of 50% and a complete response rate(CR) of 36%.
在所有22名可评估患者中，数据显示客观缓解率（ORR）为50％，完全缓解率（CR）为36％。

The New England Journal paper reports on 75 evaluable patients between 3 to 21 years of age with relapsed or treatment refractory B-cell ALL.
新英格兰期刊论文报道了75例3-21岁可复发或治疗难治性B细胞ALL的可评估患者。

Of the 106 evaluable aneurysms that were treated with one or more Pipeline devices, 73.6% completely closed(p-value< .0001) without the use of an alternative treatment.
对106例可评估动脉瘤置入一个或多个Pipeline器械进行治疗，其中73.6%的动脉瘤完全闭塞（p值<.0001），无需采用其他替代疗法进行治疗。

The overall response rate of evaluable patients was 54 percent, with 40 percent achieving a complete response.
可评估患者的总体反应率为54％，其中40％达到完全反应。

Five patients were not evaluable for objective response but were evaluable and met the criteria for stable disease.
五名患者无法评估客观反应，但可以评估并符合稳定疾病的标准。

Of the 129 participants who contributed evaluable data to the study, a total of 37(28.7%) presented with 53 DFU(0.62 DFU/participant/year).
在为研究提供可评估数据的129名参与者中，共有37名(28.7%)出现了53名DFU(0.62DFU/参与者/年)。

Between June 2014 and July 2017, 102 evaluable patients(65 percent male; median age 60 years) were randomized and received treatment every two weeks.
年6月至2017年7月，102名可评估患者（65%男性，中位年龄60岁）被随机分组，每两周接受一次治疗。

In the open-label trial, 76 evaluable patients from 4 sites in Australia were enrolled into 3 cohorts between November 2014 and April 2017.
在开放标签试验中，来自澳大利亚4个地点的76名可评估患者被纳入3个队列中，在2014年11月至2017年4月之间。

Preliminary results in 17 efficacy evaluable patients showed an overall response rate(ORR) of 76%(13/17) and a disease control rate(DCR) of 100%(17/17).
初步结果显示，在17例可评估疗效的受试者中，总缓解率（ORR）为76%（13/17），疾病控制率（DCR）达到100%（17/17）。